ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Emend's Emergence"
Episode Synopsis
The Landmarks of OncoPharm series returns to discuss 2 pivotal trials that ushered in the age of aprepitant and NK-1 receptor anagonists for CINV.
Aprepitant in HEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2003.01.095
Aprepitant in MEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.09.050
Aprepitant in HEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2003.01.095
Aprepitant in MEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.09.050
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust